Symfo

Cardionics

Following the introduction of the concept papers on QTc prolongation in 2001, it became clear that cardiovascular safety assessment would become a critical step in the drug development process. Without demonstrating the effect on QTc prolongation, the Clinical Trial industry runs the risk of a delay in approval of their compounds and possible denial.

Cardionics quickly realized that the future would be digital and this is where it has focused its activity. Having offered digital ECG solutions since 1984, Cardionics has become well-known in the field. From phase I to phase IV, we equip the Contract Research Organizations (CRO's) but also the sponsors with our ECG devices, acquisition and interpretation software's and QT analysis software's.

In addition, we offer fully digital capabilities throughout the recording, transmission and interpretation of ECGs. Cardionics S.A. Rue Gabrielle Petit, 4. Bte2.1080 Brussels. Belgium.

For more information visit their website at: http://www.cardionics.be/

Tel: +32 2 426 75 75.
Fax: +32 2 426 40 40.
E-mail: florence.degreef@cardionics.be